The plant investigation is in process.
A supplemental mdr will be submitted upon completion of this activity.
clinical investigation: based on the available information, there is a temporal and a likely causal relationship between the fresenius optiflux 180nre dialyzer and the patient¿s reaction (characterized by tongue swelling, shortness of breath and difficulty talking during the hd treatment).
Although rare, hypersensitivity or anaphylactoid reactions to optiflux dialyzers are a known risk during hemodialysis.
There is no evidence of an optiflux 180nre dialyzer product deficiency or malfunction.
Additionally, although the patient experienced an adverse reaction during treatment, there is no allegation of a product malfunction or deficiency related to this event.
|
A user facility clinical manager reported a hemodialysis (hd) patient attended regularly scheduled dialysis treatment.
Pre vs 118/78, pulse 106, temp 99.
1.
At approximately 10:34 dialysis initiated via a left upper arm avf.
Within approximately 20 minutes, the patient stated that the tongue was swelling.
The patient also had shortness of breath and difficulty speaking.
Oxygen was provided, 911 called, and dialysis was terminated.
Blood pressure 103/64, pulse 104.
The patient was transported to the emergency room and later released.
The patient recovered.
Upon follow up, the clinical manager stated the patient did not experience any reaction until the treatment on (b)(6) 2019 with use of the optiflux 180nre dialyzer (the same dialyzer used for all previous treatments).
The patient did not require hospital admission and was in the emergency room (er) for less than 24 hours prior to being discharged.
The treatment received in the er is unknown.
The patient continued hd treatment afterwards.
|